Sarcopenia as a predictor of chemotherapy toxicity in patients with ovarian cancer receiving platinum and taxane-based chemotherapy.

被引：0
|
作者：
Tucker, Katherine
Staley, Stuart-Allison Moffat
Newton, Meredith
Ertel, Michelle
Zhang, Yingao
Doherty, Irene
Gehrig, Paola A.
机构：
[1] Univ N Carolina, Div Gynecol Oncol, Chapel Hill, NC USA
[2] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC USA
[4] CHEORS, Chapel Hill, NC USA
[5] Univ N Carolina, Chapel Hill, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e17035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17035
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pharmacogenetic assessment of toxicity in patients treated with taxane-based chemotherapy for solid tumors
    Durante, V.
    Giusti, R.
    Sini, V.
    Angelini, S.
    Pellegrini, P.
    Gentile, G.
    Simmaco, M.
    Marchetti, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S205 - S205
  • [22] Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review
    Fernandes, Ricardo
    Mazzarello, Sasha
    Hutton, Brian
    Shorr, Risa
    Majeed, Habeeb
    Ibrahim, Mohammed F. K.
    Jacobs, Carmel
    Ong, Michael
    Clemons, Mark
    SUPPORTIVE CARE IN CANCER, 2016, 24 (08) : 3633 - 3650
  • [23] Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells
    Justyna Mikuła-Pietrasik
    Anna Witucka
    Martyna Pakuła
    Paweł Uruski
    Beata Begier-Krasińska
    Arkadiusz Niklas
    Andrzej Tykarski
    Krzysztof Książek
    Cellular and Molecular Life Sciences, 2019, 76 : 681 - 697
  • [24] Neoadjuvant Taxane-Based Combination Chemotherapy in Patients With Advanced Penile Cancer
    Djajadiningrat, Rosa S.
    Bergman, Andries M.
    van Werkhoven, Erik
    Vegt, Erik
    Horenblas, Simon
    CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : 44 - 49
  • [25] Reported Bone Pain in Patients with Breast Cancer Receiving Taxane-Based Chemotherapy in Clinical Trials of Pegfilgrastim
    Schwartzberg, L. S.
    Mo, M.
    Harms, R.
    Vogel, C. L.
    CANCER RESEARCH, 2009, 69 (24) : 576S - 576S
  • [26] GUT MICROBIOME AND SYMPTOM BURDEN IN WOMEN RECEIVING TAXANE-BASED CHEMOTHERAPY FOR BREAST CANCER
    Cherwin, Catherine
    Hoang, Jemmie
    ONCOLOGY NURSING FORUM, 2020, 47 (02)
  • [27] Cisplatin/taxane or carboplatin/taxane-based chemotherapy in advanced cervical cancer
    Petrelli, F.
    Lorusso, D.
    Coinu, A.
    Cabiddu, M.
    Ghilardi, M.
    Borgonovo, K.
    Cremonesi, M.
    Raspagliesi, F.
    Barni, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S729 - S730
  • [28] The role of taxane-based chemotherapy in the treatment of prostate cancer
    Huebner, Nicolai A.
    Shariat, Shahrokh F.
    Resch, Irene
    Gust, Kilian
    Kramer, Gero
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 527 - 533
  • [29] Profiles of ovarian cancer patients that benefit from taxane-platinum and platinum-based chemotherapy
    Markowska, J.
    Bidziaski, M.
    Stelmachow, J.
    Kraszewska, E.
    Ziolkowska-Seta, I.
    Madry, R.
    Timorek, A.
    Rembiszewska, A.
    Kupryjaaczyk, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy
    Autio, K. A.
    Naing, A.
    Hung, A.
    Oft, M.
    Leveque, J.
    Falchook, G. S.
    ANNALS OF ONCOLOGY, 2018, 29
12345